Where can I buy Amgen stock?
Shares of AMGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Amgen's stock price today?
What are analysts'1 year price targets for Amgen's stock?
20 analysts have issued 1 year price objectives for Amgen's stock. Their predictions range from $189.00 to $243.00. On average, they expect Amgen's stock price to reach $217.29 in the next twelve months. This suggests a possible upside of 6.9% from the stock's current price.
What is Amgen known for?
Amgen therapeutics have changed the practice of medicine, helping millions of people around the world in the fight against cancer, kidney disease, rheumatoid arthritis, and other serious illnesses. With a deep and broad pipeline of potential new medicines, Amgen remains committed to advancing science to dramatically improve people's lives.
When was the last time Amgen increased its dividend?
The most recent change in Amgen's dividend was an increase of $0.18 on Friday, December 3, 2021. What is Amgen's dividend payout ratio? View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks.
See more
Is Amgen a good stock to buy?
Amgen Inc. may be undervalued. Its Value Score of B indicates it would be a good pick for value investors. The financial health and growth prospects of AMGN, demonstrate its potential to outperform the market. It currently has a Growth Score of A.
Is Amgen a buy sell or hold?
Amgen has received a consensus rating of Hold. The company's average rating score is 2.14, and is based on 3 buy ratings, 10 hold ratings, and 1 sell rating.
Is AMGN overvalued?
Price to Book Ratio PB vs Industry: AMGN is overvalued based on its Price-To-Book Ratio (137.4x) compared to the US Biotechs industry average (1.4x).
Is Amgen undervalued?
At present, Amgen Inc. has a (ttm) net profit margin of 35.5% and is trading at a P/S ratio of 5.63. This suggests that the company is undervalued relative to the net profit it derives from its revenues.
What ETF is AMGN in?
(AMGN). ETF holdings data are updated once a day, and are subject to change....Unlock all 428 ETFs with exposure to Amgen Inc. ( AMGN)TickerIBBQETFInvesco Nasdaq Biotechnology ETFETF Database CategoryN/AExpense Ratio0.19%Weighting9.50%24 more columns
Is Merck stock a good buy?
Based on CAN SLIM rules for investing, yes, Merck stock is a buy right now. Shares have surged above their buy point, again. Promisingly, Merck's sales and earnings met CAN SLIM guidelines in the first quarter, and are expected to do the same in the current quarter.
Will Amgen stock go up?
Stock Price Forecast The 21 analysts offering 12-month price forecasts for Amgen Inc have a median target of 245.00, with a high estimate of 295.00 and a low estimate of 185.00. The median estimate represents a +6.17% increase from the last price of 230.77.
Is Amgen growing?
Amgen is projecting compound annual growth in mid-single digits through the end of this decade. Considering the company reported 2021 revenue at $26 billion, that level of growth would get Amgen to roughly $35 billion in revenue in 2030.
Is Amgen publicly traded?
Other products include Epogen, Aranesp, Sensipar/Mimpara, Nplate, Vectibix, Prolia and XGEVA....Amgen.Headquarters in Thousand Oaks, CaliforniaTypePublicTraded asNasdaq: AMGN NASDAQ-100 component DJIA component S&P 100 component S&P 500 componentISINUS0311621009IndustryBiotechnology14 more rows
Why is Amgen so successful?
The Bottom Line. Amgen and its development team have offered relief to many patients that are suffering. By setting its resources to alleviating physical pain, the company has found its market and generated tremendous profits. For the fiscal year 2019, the company reported total revenues of $23.9 billion.
About Amgen
Amgen (NASDAQ:AMGN) Frequently Asked Questions
Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture and marketing of human therapeutics.
Scared of the Bear? Buy These 3 Healthcare Stocks
18 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Amgen in the last twelve months. There are currently 2 sell ratings, 11 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" Amgen stock.
Ligand (LGND) Q4 Earnings Beat, OmniAb Spin-Off in 1H22
Healthcare is the smart play in this bear market. Here's why these three Fool.com contributors like Doximity, Amgen, and Novocure.
Mirati (MRTX) Down on Longer Review Period for Adagrasib NDA
Ligand (LGND) reports encouraging fourth-quarter 2021 numbers by beating estimates on both counts. However, royalties decline. The company plans to complete business separation in the first half of 2022.
Nasdaq Global Select
The FDA accepts Mirati's (MRTX) NDA for its lung cancer candidate, adagrasib. A decision is expected by Dec 14, 2022.
Environmental, Social, and Governance Rating
One of the pioneers of the biotech industry, Amgen is now one of the world's largest pharmaceutical companies, with more than a dozen products focused on cancer, inflammation, neurology, cardiology, and more.
Business Summary
"B" score indicates good relative ESG performance and an above-average degree of transparency in reporting material ESG data publicly and privately. Scores range from AAA to D.
Signals & Forecast
One of the pioneers of the biotech industry, Amgen is now one of the world's largest pharmaceutical companies, with more than a dozen products focused on cancer, inflammation, neurology, cardiology, and more.
Support, Risk & Stop-loss
There are few to no technical positive signals at the moment. The Amgen Inc. stock holds sell signals from both short and long-term moving averages giving a more negative forecast for the stock. Also, there is a general sell signal from the relation between the two signals where the long-term average is above the short-term average.
Is Amgen Inc. stock A Buy?
Amgen Inc. finds support from accumulated volume at $219.25 and this level may hold a buying opportunity as an upwards reaction can be expected when the support is being tested.
About Amgen Inc
The Amgen Inc. stock holds several negative signals and despite the positive trend, we believe Amgen Inc. will perform weakly in the next couple of days or weeks. Therefore, we hold a negative evaluation of this stock.
Golden Star Signal
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of illness in the areas of oncology/hematology, cardiovascular, inflammation, bone health, nephrology, and neuroscience.
Top Fintech Company
This unique signal uses moving averages and adds special requirements that convert the very good Golden Cross into a Golden Star.
What is Amgen's dividend yield?
featured in The Global Fintech Index 2020 as the top Fintech company of the country.
When is Amgen's next dividend payment?
The current dividend yield for Amgen (NASDAQ:AMGN) is 3.45%. Learn more
When was Amgen's most recent dividend payment?
Amgen's next quarterly dividend payment of $1.94 per share will be made to shareholders on Tuesday, March 8, 2022.
What track record does Amgen have of raising its dividend?
Amgen's most recent quarterly dividend payment of $1.76 per share was made to shareholders on Wednesday, December 8, 2021.
When did Amgen last increase or decrease its dividend?
Amgen (NASDAQ:AMGN) has increased its dividend for the past 11 consecutive years.
Innovative Medicines
The most recent change in Amgen's dividend was an increase of $0.18 on Friday, December 3, 2021.
Transformative Research
We have a presence in approximately 100 countries and regions worldwide and our innovative medicines have reached millions of people in the fight against serious illnesses. We focus on six therapeutic areas: cardiovascular disease, oncology, bone health, neuroscience, nephrology and inflammation.
World-Class Biomanufacturing
Understanding the fundamental biological mechanisms of disease is a defining feature of Amgen's discovery research efforts—and a major contributor to the development of Amgen's deep and broad pipeline of potential new medicines.
Sales
Risks
- 17 Wall Street analysts have issued 12 month price objectives for Amgen's stock. Their forecasts range from $179.00 to $232.00. On average, they anticipate Amgen's share price to reach $207.4706 in the next year. This suggests a possible upside of 20.7% from the stock's current price. View Analyst Price Targets for Amgen.
Ratings
- 17 Wall Street analysts have issued \"buy,\" \"hold,\" and \"sell\" ratings for Amgen in the last year. There are currently 9 hold ratings and 8 buy ratings for the stock, resulting in a consensus recommendation of \"Hold.\" View Analyst Ratings for Amgen.
Reception
- Media stories about AMGN stock have trended somewhat positive on Sunday, InfoTrie Sentiment Analysis reports. The research firm identifies negative and positive press coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most f…
Ownership
- Amgen's stock is owned by a number of of institutional and retail investors. Top institutional investors include BlackRock Inc. (7.56%), Wells Fargo & Company MN (1.23%), LSV Asset Management (0.64%), Sumitomo Mitsui Trust Holdings Inc. (0.41%), Dimensional Fund Advisors LP (0.39%) and Parametric Portfolio Associates LLC (0.38%). Company insiders that own Amge…
Business
- Amgen has a market capitalization of $104.82 billion and generates $23.75 billion in revenue each year. The medical research company earns $8.39 billion in net income (profit) each year or $14.40 on an earnings per share basis. Amgen employs 21,500 workers across the globe.
Infrastructure
- Amgen's mailing address is ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA, 91320. The medical research company can be reached via phone at 805-447-1000 or via email at [email protected].